WILMINGTON, DE — Incyte (Nasdaq: INCY) announced executive leadership changes, including the appointment of Pablo J. Cagnoni, M.D., as president and global head of research and development, as the company restructures roles to support its long-term growth strategy.
Cagnoni will continue to lead research and development while taking on additional responsibilities for enterprise-wide strategy and operations, the company said.
Steven Stein, M.D., was appointed executive vice president, chief medical officer and head of late-stage development, where he will oversee late-stage programs across hematology, oncology and immunology, as well as global medical affairs.
Mohamed Issa, Pharm.D., was named executive vice president and head of U.S. commercial, expanding his role to include both oncology and immunology businesses as part of a combined commercial organization.
The company said the integration of its U.S. commercial teams is intended to align operations and support future product launches.
Bill Meury, chief executive officer of Incyte, said the leadership changes reflect the executives’ contributions and are intended to support execution of the company’s strategy.
“These appointments reflect the significant contributions Pablo, Steven and Mohamed have made to Incyte,” Meury said.
As part of the transition, Matteo Trotta, executive vice president and general manager of U.S. dermatology, will leave the company following a transition period.
Incyte develops and commercializes therapies across hematology, oncology, inflammation and autoimmune disease areas.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.